Calendar

Cloudflare’s reported Q2 2026 revenue growth and a $736.8M Q3 revenue consensus provide a credible business backdrop, but the stock fell sharply into the event: it lost roughly 15.5% from Oct. 26 to Oct. 30, including a high-volume down day. Required positive tape and estimate-upside signals are not supported.

ABNB has a small positive whisper-versus-consensus gap and recent company guidance describes strong revenue growth, but the guidance midpoint is slightly below the checked revenue consensus. The stock fell about 4.4% over five sessions, had no close above the 0.75 close-location threshold in the latest three sessions, and no confirmed 1.5x volume session; it does not qualify despite a supportive XLY tape.

EOG has upward EPS estimate revisions, a credible Q3 consensus, and a strong Oct. 30 close, but available checks did not establish positive revenue revisions or a recent >1.5x-volume accumulation day. The company has scheduled its Q3 results for Nov. 5 after close; its IR page separately lists a Nov. 6 results call.

Lumentum's September-quarter EPS estimate rose from $4.21 to $4.22 over the last month, and its prior company guidance midpoint for $1.25B revenue is in line with reported consensus; management cited accelerating AI-driven optical demand and the stock advanced sharply over the preceding five sessions. However, the late-week reversal and lack of a verified normal-volume comparator temper the setup, while valuation and execution risks remain material.

Simon has positive, though non-uniform, estimate momentum: checked consensus showed EPS up 1.74% and revenue up 3.69% over three months, and its latest reported quarter showed 96.0% occupancy, higher retailer sales, and raised full-year FFO guidance. The stock gained about 2.4% over five sessions and closed near the top of its Oct 30 range, but a normal-volume comparison was unavailable and its recent earnings history is uneven.

DVN has positive near-term estimate revisions, rising revenue expectations, four recent EPS beats per Zacks, and an official Nov. 5 reporting date; the stock also strengthened into the event. However, earnings-whisper EPS is below some consensus figures and the shares lagged the energy sector over the past month, while commodity exposure and transaction execution leave meaningful uncertainty.

Earnings Whispers reports a $1.48 whisper against $1.39 consensus, while the prior quarter had strong reported growth; however, no reliable pre-event revenue-revision, verified close-location, or volume-accumulation evidence was found for this screen, and the supplied latest close does not establish recent strength. The positive whisper alone is insufficient for qualification.

ED's reported date and consensus figures were available, and the recent close rose with XLU supportive; Con Edison had reaffirmed its 2026 adjusted EPS guidance. But no positive EPS revision, ESP, whisper, or revenue-upside signal was verified, and none of the last three checked sessions closed in the upper quarter of its range.

A pre-event Zacks article says the estimate-revision combination points toward a likely EPS beat, and recent annualized recovery expectations offer a possible cyclical catalyst. However, exact revision and current-quarter revenue consensus/upside evidence was not verifiable in the checked results, while Oct. 30 brought a high-volume 4.66% selloff and a weak close; it fails the required tape confirmation.

Live Nation has strong operating indicators ahead of the report: the latest available filing said 2026 event ticket sales were pacing 11% higher and deferred revenue reached a second-quarter record, while the stock recovered into Oct. 30 on a large-volume up day. But current-quarter revenue consensus estimates varied across checked providers and no positive EPS revision/ESP/whisper was verified; score remains below the required threshold.

The supplied Nov. 5 date conflicts with checked earnings sources: Earnings Whispers and MarketBeat indicate Nov. 4, while another estimate page shows Nov. 5 and cautions the date may move. Consensus estimates exist, but no positive revisions or required tape confirmation were established; reject on unconfirmed event date and incomplete signals.

MRNA has a modestly favorable EPS revision snapshot and a recent high-volume rebound, but the checked calendar sources describe Nov. 6 as estimated rather than company-confirmed, and no positive revenue revision or upside indicator was verified. The Oct. 22 melanoma-trial data leak coincided with a 17.57% drop and unusually high volume, leaving a volatile, event-driven tape.

Record Q2 fundraising and 20% fee-related-earnings growth, alongside a rising recent share price and several analyst target cuts, create a constructive but mixed backdrop. The checked sources support EPS and revenue consensus, but do not establish positive estimate revisions or an upside surprise signal; recent volume also falls short of a verified accumulation trigger.

Humana's primary IR estimate table showed near-flat Q3 EPS revisions and a credible consensus source provides EPS and revenue estimates, but the stock weakened into the event and underperformed the rising XLV. Medical-cost and Medicare policy uncertainty remain material, while recent tape did not confirm accumulation.

Vistra has a company-confirmed Nov. 6 report date and a strongly positive 30-day Q3 EPS revision, alongside long-term power-demand catalysts. However, shares declined about 5.4% from Oct. 26 through Oct. 30, recent closes were weak in their daily ranges, and the latest quarter missed consensus materially. Positive revisions alone do not offset the poor pre-event tape and limited recent execution evidence.

The initial earnings reaction was negative: BAC fell about 4.7% on October 14 ([market report](https://www.kiplinger.com/investing/stocks/nasdaq-nosedives-as-ai-boosts-consumer-prices-stock-market-today)). It rose about 1% in October 15 trading according to [post-print coverage](https://www.benzinga.com/news/26/10/62393957/bank-of-america-analysts-slash-their-forecasts-following-weak-q3-results), but the supplied October 16 close of $51.23 does not establish a sustained recovery. Multiple analyst target cuts and at least one reported EPS-estimate cut provide a more concrete negative revision read than the prior draft, although a refreshed broad consensus is unavailable. The October 14 SEC-filed release confirms the earnings drivers; the company-hosted call transcript could not be retrieved for detailed guidance verification. Social, options, short-interest and employee metrics were not supplied, and their zero entries mean unavailable, not neutral readings.

Company-reported Q3 results and the initial analyst target revisions are positive, and the October 16 close held above the October 13 pre-release close. The move cannot be attributed solely to earnings from the available evidence. No sufficiently supported social, options, short-interest or employee measures were supplied; the zero-valued fields above mean unavailable, not neutral readings. The packet's stored earnings-document rows are third-party articles, not an official transcript or company release. https://stockanalysis.com/stocks/blk/history/ https://stockanalysis.com/stocks/blk/forecast/

The October 16 close was $29.15, down 1.0% from October 15 despite an adjusted EPS and revenue beat; that move alone does not establish why shares fell. [Price history](https://chartexchange.com/symbol/nasdaq-wafd/historical/) [AP earnings snapshot](https://finance.yahoo.com/markets/stocks/articles/wafd-fiscal-q4-earnings-snapshot-004710575.html) One reported post-print revision is Keefe Bruyette's target cut to $34 from $40 with Market Perform maintained; broader estimate revisions are unavailable. [Keefe Bruyette target report](https://www.tipranks.com/news/the-fly/wafd-price-target-lowered-to-34-from-40-at-keefe-bruyette-thefly-news) Social, options and short-interest measures were not supplied; zero values in the structured sentiment fields denote unavailable data, not neutral readings.

T+1 reaction is mixed rather than a clean rerating: PNC closed October 15 at $214.94, about 0.4% below the prior $215.80 close despite the adjusted-EPS beat and raised loan/revenue outlook. One reported target cut accompanies raised EPS estimates, so it should not be generalized to all analysts. Social, options, short-interest and employee readings were not supplied; their zero placeholders are unavailable data, not observed neutral sentiment. ([historical price](https://stockanalysis.com/stocks/pnc/history/); [reported analyst revision](https://www.investing.com/news/analyst-ratings/raymond-james-cuts-pnc-financial-stock-price-target-on-rate-outlook-93CH-4952677))

The earnings release supports a mixed-to-improving operating view, not a wholesale reversal of the prior cautious thesis or the deterministic negative directional prior. Shares were reported up about 2.4% premarket on October 16 versus the $40.42 October 15 close; a regular-session post-print move is not yet established. Barclays' $55 initiation preceded the print, and verified post-print analyst revisions are unavailable. Sentiment fields shown as zero are unavailable-data placeholders, not neutral measurements; social coverage is insufficient. [Premarket report](https://www.investing.com/news/stock-market-news/why-is-alcoa-stock-climbing-today-93CH-4953554)

This is a pre-earnings monitoring view, not a post-print reaction assessment: Herc's [investor-relations calendar](https://ir.hercrentals.com/overview/default.aspx) lists October 27 for Q3 results. The packet supplies an October 15 close of $124 but no post-release price move, Q3 surprise, or subsequent analyst revisions. Sentiment metrics other than low observed headline coverage are unavailable; the zero numeric entries above denote missing data, not neutral measured readings. The deterministic positive prior warrants attention, but its elevated thesis-change score appears tied to a misdated trigger rather than confirmed new results.